Glaucius Oliva

Cloning, characterization and preliminary crystallographic analysis of Leishmania hypoxanthine-guanine phosphoribosyltransferase.

In silico screening strategies for novel inhibitors of parasitic diseases.

Molecular docking and structure-based drug design strategies.

Crystal structure of Zika virus NS5 RNA-dependent RNA polymerase.

New Molecular Targets and Strategies for Antimalarial Discovery.

Discovery of Marinoquinolines as Potent and Fast-Acting Plasmodium falciparum Inhibitors with in Vivo Activity.

Structural and mechanistic insight from antiviral and antiparasitic enzyme drug targets for tropical infectious diseases.

Phthalimide Derivatives with Bioactivity against : Synthesis, Evaluation, and Computational Studies Involving Cytochrome Inhibition.

Discovery of Potent, Reversible, and Competitive Cruzain Inhibitors with Trypanocidal Activity: A Structure-Based Drug Design Approach.

A diarylamine derived from anthranilic acid inhibits ZIKV replication.

Antiplasmodial profile of selected compounds from Malaria Box: in vitro evaluation, speed of action and drug combination studies.

Structural characterization and polymorphism analysis of the NS2B-NS3 protease from the 2017 Brazilian circulating strain of Yellow Fever virus.

Reporter Replicons for Antiviral Drug Discovery against Positive Single-Stranded RNA Viruses.

Flavonoids from Pterogyne nitens as Zika virus NS2B-NS3 protease inhibitors.

Discovery of an imidazonaphthyridine and a riminophenazine as potent anti-Zika virus agents through a replicon-based high-throughput screening.

A Crystallographic Snapshot of SARS-CoV-2 Main Protease Maturation Process.

Development of Machine Learning Models and the Discovery of a New Antiviral Compound against Yellow Fever Virus.

Machine Learning Models Identify Inhibitors of SARS-CoV-2.

Non-Toxic Dimeric Peptides Derived from the Bothropstoxin-I Are Potent SARS-CoV-2 and Papain-like Protease Inhibitors.